Which has better valuation & earnings, RXST or INMD?

InMode has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $127.48M 1.69 -$38.94M -$1.13 N/A InMode $374.64M 2.33 $93.83M $1.36 11.15

Is RXST or INMD more profitable?

InMode has a net margin of 23.27% compared to RxSight's net margin of -36.58%. InMode's return on equity of 13.47% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% InMode 23.27% 13.47% 11.95%

Does the media refer more to RXST or INMD?

In the previous week, InMode had 1 more articles in the media than RxSight. MarketBeat recorded 5 mentions for InMode and 4 mentions for RxSight. RxSight's average media sentiment score of 1.23 beat InMode's score of 0.91 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InMode 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXST or AVR?

In the previous week, Anteris Technologies Global had 1 more articles in the media than RxSight. MarketBeat recorded 5 mentions for Anteris Technologies Global and 4 mentions for RxSight. Anteris Technologies Global's average media sentiment score of 1.57 beat RxSight's score of 1.23 indicating that Anteris Technologies Global is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anteris Technologies Global 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, BBNX or RXST?

RxSight has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $110.24M 6.41 -$73.20M -$1.51 N/A RxSight $127.48M 1.69 -$38.94M -$1.13 N/A

Is BBNX or RXST more profitable?

RxSight has a net margin of -36.58% compared to Beta Bionics' net margin of -60.27%. RxSight's return on equity of -17.01% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% RxSight -36.58% -17.01% -15.12%

Does the media prefer BBNX or RXST?

In the previous week, Beta Bionics and Beta Bionics both had 4 articles in the media. RxSight's average media sentiment score of 1.23 beat Beta Bionics' score of 1.07 indicating that RxSight is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, RXST or SIBN?

SiBone has higher revenue and earnings than RxSight. SiBone is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $127.48M 1.69 -$38.94M -$1.13 N/A SiBone $206.22M 3.57 -$18.90M -$0.39 N/A

Is RXST or SIBN more profitable?

SiBone has a net margin of -8.10% compared to RxSight's net margin of -36.58%. SiBone's return on equity of -9.56% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% SiBone -8.10% -9.56% -7.06%

Does the media refer more to RXST or SIBN?

In the previous week, RxSight and RxSight both had 4 articles in the media. SiBone's average media sentiment score of 1.31 beat RxSight's score of 1.23 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXST or SSII?

In the previous week, SS Innovations International had 5 more articles in the media than RxSight. MarketBeat recorded 9 mentions for SS Innovations International and 4 mentions for RxSight. RxSight's average media sentiment score of 1.23 beat SS Innovations International's score of 0.49 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SS Innovations International 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

RxSight (RXST) Competitors

$5.19 -0.18 (-3.35%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$5.21 +0.02 (+0.39%)

As of 07/24/2026 07:34 PM Eastern

Compare

RXST vs. INMD, AVR, BBNX, SIBN, and SSII

Should you buy RxSight stock or one of its competitors? MarketBeat compares RxSight with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RxSight include InMode (INMD), Anteris Technologies Global (AVR), Beta Bionics (BBNX), SiBone (SIBN), and SS Innovations International (SSII). These companies are all part of the "medical equipment" industry.

How does RxSight compare to InMode?

RxSight (NASDAQ:RXST) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

InMode has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.69	-$38.94M	-$1.13	N/A
InMode	$374.64M	2.33	$93.83M	$1.36	11.15

RxSight currently has a consensus price target of $8.89, indicating a potential upside of 71.27%. InMode has a consensus price target of $16.00, indicating a potential upside of 5.47%. Given RxSight's higher possible upside, equities research analysts plainly believe RxSight is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.8% of RxSight shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

InMode has a net margin of 23.27% compared to RxSight's net margin of -36.58%. InMode's return on equity of 13.47% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
InMode	23.27%	13.47%	11.95%

RxSight has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, InMode has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

In the previous week, InMode had 1 more articles in the media than RxSight. MarketBeat recorded 5 mentions for InMode and 4 mentions for RxSight. RxSight's average media sentiment score of 1.23 beat InMode's score of 0.91 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InMode	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InMode beats RxSight on 11 of the 16 factors compared between the two stocks.

How does RxSight compare to Anteris Technologies Global?

RxSight (NASDAQ:RXST) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

RxSight has higher revenue and earnings than Anteris Technologies Global. RxSight is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.69	-$38.94M	-$1.13	N/A
Anteris Technologies Global	$1.85M	427.55	-$94.14M	-$2.23	N/A

RxSight has a net margin of -36.58% compared to Anteris Technologies Global's net margin of -5,148.78%. RxSight's return on equity of -17.01% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%

RxSight has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Anteris Technologies Global had 1 more articles in the media than RxSight. MarketBeat recorded 5 mentions for Anteris Technologies Global and 4 mentions for RxSight. Anteris Technologies Global's average media sentiment score of 1.57 beat RxSight's score of 1.23 indicating that Anteris Technologies Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anteris Technologies Global	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

RxSight currently has a consensus target price of $8.89, indicating a potential upside of 71.27%. Anteris Technologies Global has a consensus target price of $16.00, indicating a potential upside of 96.80%. Given Anteris Technologies Global's stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

RxSight and Anteris Technologies Global tied by winning 8 of the 16 factors compared between the two stocks.

How does RxSight compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

78.8% of RxSight shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Beta Bionics presently has a consensus price target of $20.30, indicating a potential upside of 28.08%. RxSight has a consensus price target of $8.89, indicating a potential upside of 71.27%. Given RxSight's higher possible upside, analysts clearly believe RxSight is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

RxSight has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$110.24M	6.41	-$73.20M	-$1.51	N/A
RxSight	$127.48M	1.69	-$38.94M	-$1.13	N/A

RxSight has a net margin of -36.58% compared to Beta Bionics' net margin of -60.27%. RxSight's return on equity of -17.01% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
RxSight	-36.58%	-17.01%	-15.12%

In the previous week, Beta Bionics and Beta Bionics both had 4 articles in the media. RxSight's average media sentiment score of 1.23 beat Beta Bionics' score of 1.07 indicating that RxSight is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beta Bionics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market. Comparatively, RxSight has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Summary

RxSight beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does RxSight compare to SiBone?

RxSight (NASDAQ:RXST) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

SiBone has a net margin of -8.10% compared to RxSight's net margin of -36.58%. SiBone's return on equity of -9.56% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
SiBone	-8.10%	-9.56%	-7.06%

In the previous week, RxSight and RxSight both had 4 articles in the media. SiBone's average media sentiment score of 1.31 beat RxSight's score of 1.23 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RxSight currently has a consensus target price of $8.89, suggesting a potential upside of 71.27%. SiBone has a consensus target price of $23.50, suggesting a potential upside of 41.40%. Given RxSight's higher probable upside, research analysts clearly believe RxSight is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

78.8% of RxSight shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 4.0% of SiBone shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

SiBone has higher revenue and earnings than RxSight. SiBone is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.69	-$38.94M	-$1.13	N/A
SiBone	$206.22M	3.57	-$18.90M	-$0.39	N/A

RxSight has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Summary

SiBone beats RxSight on 11 of the 15 factors compared between the two stocks.

How does RxSight compare to SS Innovations International?

RxSight (NASDAQ:RXST) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

SS Innovations International has lower revenue, but higher earnings than RxSight. SS Innovations International is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.69	-$38.94M	-$1.13	N/A
SS Innovations International	$48.47M	14.33	-$12.13M	-$0.05	N/A

RxSight has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.96, indicating that its share price is 296% less volatile than the broader market.

RxSight presently has a consensus price target of $8.89, suggesting a potential upside of 71.27%. SS Innovations International has a consensus price target of $7.00, suggesting a potential upside of 101.73%. Given SS Innovations International's higher possible upside, analysts clearly believe SS Innovations International is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SS Innovations International has a net margin of -20.69% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
SS Innovations International	-20.69%	-23.00%	-13.18%

In the previous week, SS Innovations International had 5 more articles in the media than RxSight. MarketBeat recorded 9 mentions for SS Innovations International and 4 mentions for RxSight. RxSight's average media sentiment score of 1.23 beat SS Innovations International's score of 0.49 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SS Innovations International	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RxSight beats SS Innovations International on 9 of the 16 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$214.85M	$7.28B	$6.86B	$12.25B
Dividend Yield	N/A	1.33%	2.67%	9.79%
P/E Ratio	-4.59	48.63	27.14	23.64
Price / Sales	1.69	96.85	517.01	89.03
Price / Cash	N/A	25.71	50.54	59.64
Price / Book	0.77	6.73	10.28	6.07
Net Income	-$38.94M	$162.27M	$3.60B	$331.99M
7 Day Performance	-6.49%	-5.05%	-1.27%	-0.63%
1 Month Performance	1.17%	-5.86%	-0.37%	-2.00%
1 Year Performance	-34.88%	-2.88%	18.30%	13.62%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	3.8246 of 5 stars	$5.19 -3.4%	$8.89 +71.3%	-34.6%	$214.85M	$127.48M	N/A	220	Positive News
INMD InMode	1.353 of 5 stars	$15.30 -0.4%	$16.00 +4.6%	+4.4%	$879.16M	$370.49M	11.25	480
AVR Anteris Technologies Global	3.1381 of 5 stars	$8.07 -1.8%	$16.00 +98.3%	+147.9%	$785.53M	$1.91M	N/A	138	News Coverage
BBNX Beta Bionics	3.2363 of 5 stars	$17.61 -1.2%	$20.30 +15.3%	+9.8%	$784.70M	$100.25M	N/A	294	News Coverage
SIBN SiBone	3.7156 of 5 stars	$17.16 +0.2%	$23.50 +36.9%	-4.3%	$761.09M	$200.93M	N/A	350	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors

RXST vs. INMD, AVR, BBNX, SIBN, and SSII

How does RxSight compare to InMode?

Summary

How does RxSight compare to Anteris Technologies Global?

Summary

How does RxSight compare to Beta Bionics?

Summary

How does RxSight compare to SiBone?

Summary

How does RxSight compare to SS Innovations International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Competitors

RXST vs. INMD, AVR, BBNX, SIBN, and SSII

How does RxSight compare to InMode?

Which has better valuation & earnings, RXST or INMD?

Do analysts rate RXST or INMD?

Do institutionals and insiders believe in RXST or INMD?

Is RXST or INMD more profitable?

Which has more risk & volatility, RXST or INMD?

Does the media refer more to RXST or INMD?

Summary

How does RxSight compare to Anteris Technologies Global?

Which has higher earnings and valuation, RXST or AVR?

Is RXST or AVR more profitable?

Which has more risk and volatility, RXST or AVR?

Do institutionals & insiders have more ownership in RXST or AVR?

Does the media refer more to RXST or AVR?

Do analysts rate RXST or AVR?

Summary

How does RxSight compare to Beta Bionics?

Do insiders & institutionals have more ownership in BBNX or RXST?

Do analysts prefer BBNX or RXST?

Which has stronger earnings and valuation, BBNX or RXST?

Is BBNX or RXST more profitable?

Does the media prefer BBNX or RXST?

Which has more volatility & risk, BBNX or RXST?

Summary

How does RxSight compare to SiBone?

Is RXST or SIBN more profitable?

Does the media refer more to RXST or SIBN?

Do analysts prefer RXST or SIBN?

Do institutionals and insiders hold more shares of RXST or SIBN?

Which has preferable earnings & valuation, RXST or SIBN?

Which has more risk and volatility, RXST or SIBN?

Summary

How does RxSight compare to SS Innovations International?

Do institutionals & insiders hold more shares of RXST or SSII?

Which has stronger valuation & earnings, RXST or SSII?

Which has more volatility and risk, RXST or SSII?

Do analysts prefer RXST or SSII?

Is RXST or SSII more profitable?

Does the media refer more to RXST or SSII?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools